Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030275 | 0.90 | TAAR1 (0.45) | TAAR1LTA4HPLA2G2AKCNA3HTR1B | |
| SCHEMBL27458045 | 0.89 | TAAR1 (0.44) | TAAR1LTA4HPLA2G2AKCNA3 | |
| SCHEMBL5704638 | 0.87 | KCNA3 (0.42) | TAAR1LTA4HPLA2G2AKDM4ESMN1; SMN2 | |
| SCHEMBL5251629 | 0.87 | TAAR1 (0.42) | TAAR1KCNA3 | |
| SCHEMBL920448 | 0.84 | ALDH1A1 (0.38) | TAAR1LTA4HPLA2G2AKCNA3 | |
| SCHEMBL6386653 | 0.83 | — | — | |
| SCHEMBL922260 | 0.82 | KCNA3 (0.40) | TAAR1LTA4HPLA2G2AKDM4ESMN1; SMN2 | |
| SCHEMBL27854326 | 0.81 | TAAR1 (0.46) | TAAR1LTA4HPLA2G2AKDM4ESMN1; SMN2 | |
| SCHEMBL920813 | 0.81 | KCNA3 (0.43) | TAAR1LTA4HKCNA3 | |
| SCHEMBL129009 | 0.80 | KMT2A (0.42) | LTA4HKDM4ESMN1; SMN2MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104080783-A | Pyrrole compounds | YAKULT HONSHA KK | 2014-10-01 | — | — | CN | claimed |
| CN-101784188-A | Alkynyl phenyl derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2010-07-21 | — | — | CN | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| CN-115960032-A | Aryloxy propanol amine beta-adrenaline receptor ligand with beta-arrestin biased agonistic activity and application thereof | 复旦大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-105541769-A | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2016-05-04 | — | — | CN | disclosed |
| CN-103664637-B | Be used for the treatment of ophthalmic diseases and disorderly alkynyl phenyl derivative compounds | ACUCELA INC. (US) | 2016-02-03 | — | — | CN | disclosed |
| US-20140343017-A1 | PYRROLE COMPOUND | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-11-20 | — | — | US | disclosed |
| CN-104080783-A | Pyrrole compounds | YAKULT HONSHA KK | 2014-10-01 | — | — | CN | disclosed |
| CN-103664637-A | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2014-03-26 | — | — | CN | disclosed |
| CN-101784188-B | Alkynyl phenyl derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-02-12 | — | — | CN | disclosed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
| CN-1550496-A | Acetylenic alpha-amino acid-based sulfamide hydroxamic acid TACE inhibitors | ���Ͽع�����˾ | 2004-12-01 | — | — | CN | disclosed |
| CN-1104418-C | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2003-04-02 | — | — | CN | disclosed |
| CN-1345308-A | Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID CO (US) | 2002-04-17 | — | — | CN | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343017-A1 | PYRROLE COMPOUND | TUBB3, TUBB1, TUBB | TAAR1 3218/4885LTA4H 4510/4885PLA2G2A 4811/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | TAAR1 3680/4885LTA4H 3490/4885PLA2G2A 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.